Malaysia continues to push hard to strengthen its presence in the EU’s Euro 225 billion plus import market.
TUESDAY, OCTOBER 22, FRANKFURT: A total of 10 Malaysian exhibitors will be taking part at the CPhi 2013 trade fair at Frankfurt. Malaysia’s pavilion will be in Hall 4.0 D24 and is organised by the Malaysian Ministry of Health and Malaysia External Trade Development Corporation (MATRADE).
According to S. Jai Shankar, the Trade Commissioner at MATRADE’s Frankfurt office, Malaysian pharmaceutical industry has moved up the value chain over the last decade. According to him currently the industry has the capacity to produce medicines in all dosage forms e.g. tablets (coated & non-coated), capsules (hard and soft gelatine), liquids, creams, ointments, sterile eye drops, small volume injectable (ampoules and vials), large volume infusions, dry powders for reconstitution and active pharmaceutical ingredients (API).
Local manufacturers have also developed and launched off-patent generics and herbal products using their own brands. Currently, the local industry is producing about 30 per cent of the domestic demand, as well as exporting to the Asia-Pacific Rim countries, the Middle East, Africa, Latin America and Europe. Leading Malaysian companies are also moving into the production of biologics drugs, oncology and high value-added generic compounds in-line with the growing demands in this region. 246 pharmaceutical premises with Good Manufacturing Practices certification have registered with the Malaysia”s Drug Control Authority (DCA).
According to Mr. Shankar, of these, a total of 51 premises are licensed to produce modern medicines comprising mainly analgesics, antacids, anti-hypertensive, diuretics, antibiotics and anti-histamines in the form of tablets, capsules, drops, powders, creams, ointments, injectable, syrups, ophthalmic and nasal preparations. The remaining 172 premises are licensed to produce local traditional and herbal medicines.
“Malaysia is one of the few countries in the region that have been accepted into the Pharmaceutical Inspection Cooperation/Scheme (PIC/S),” he says. The country’s exports of pharmaceutical products received a boost, especially among the member countries, which include the EU, Australia and Canada with the admission of Malaysia as a member of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Cooperation/Scheme (PIC/S) in January 2002,
There is also growing demand for Malaysia’s expertise in production of halal pharmaceuticals and Malaysia’s halal certifications. Under the Healthcare National Key Economic Area (NKEA) sector, one of the key recommendations is to promote manufacturing of pharmaceuticals. New investments in the state-of-the-art technologies and compliance with international standards have enabled Malaysian companies to be strategic outsourcing partners for MNCs. Furthermore, Malaysia has established 27 Clinical Research Centres (CRC) to conduct clinical trials, clinical epidemiology and economic research, and manage complex medical databases.
According to Mr. Shankar, essentially these developments mean Malaysian pharmaceutical companies are more than capable of now only supplying products but also a wide-range of R&D and manufacturing services to the global pharmaceutical companies. At the CPhI, Malaysia is represented by some of its largest manufactures in the pharmaceutical industry. Details of the companies are as below:
CCM PHARMACEUTICALS SDN BHD
1. Ethical, OTC and Food Supplements (all major therapeutic class and health supplements for children and adult).
2. OSD (tablet, capsule, & softgel)
DUOPHARMA (M) SDN BHD
1. Ethical range covering all major therapeutic class
2. OSD (Tablet & Capsule)
KOTRA PHARMA (M) SDN BHD
1. Axcel – prescription medicine
2. Vaxcel – prescription injectable
3. Appeton – healthcare supplements
MEDICAL DEVICES CORPORATION SDN BHD
1. Continuous Ambulatory Peritoneal Dialysis (CAPD)
2. Metabolic solution bag for Intraveneous (IV)
3. Flexible medical solutions bags Irrigation and Veterinary
NATURAL WELLNESS INDUSTRIES SDN BHD
1. Traditional herbs supplements
2. Health care products
PHARMANIAGA MANUFACTURING BERHAD
Simvastatin (Health care product) & packaging services
IDAMAN PHARMA MANUFACTURING SDN BHD
Azithromycin (Medicine) & packaging services
XEPA-SOUL PATTINSON (M) SDN BHD
AIN MEDICARE SDN BHD
1. Intravenous solutions
2. Irrigation solutions
3. Small volume products
SFS GLOBAL LOGISTICS SDN BHD
Total logistic provider for sea, air and land.
MATRADE was established on March 1, 1993 as the external trade promotion arm of Malaysia’s Ministry of International Trade and Industry (MITI). Its functions are:
-To promote, assist and develop Malaysia’s external trade with particular emphasis on the export of manufactured and semi-manufactured products and services;
-To formulate and implement export marketing strategies and trade promotion activities to promote Malaysia’s export;
-To undertake commercial intelligence and market research and create a comprehensive database of information for the improvement and development of Malaysia’s trade;
-To organise training programmes to improve the international marketing skills of Malaysian exporters;
-To enhance and protect Malaysia’s international trade investment abroad; and
-To promote, facilitate and assist in the services areas related to trade.
NOTE TO EDITORS (not to be published)
For more information, please contact:
Marketing Officer, MATRADE Frankfurt
Media Agency for content and design